Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 179

1.

Effect of cisplatin on distortion product otoacoustic emissions in Japanese patients.

Eiamprapai P, Yamamoto N, Hiraumi H, Ogino-Nishimura E, Kitamura M, Hirano S, Ito J.

Laryngoscope. 2012 Jun;122(6):1392-6. doi: 10.1002/lary.23336. Epub 2012 May 3.

PMID:
22555987
2.

Factors affecting sensitivity of distortion-product otoacoustic emissions to ototoxic hearing loss.

Reavis KM, Phillips DS, Fausti SA, Gordon JS, Helt WJ, Wilmington D, Bratt GW, Konrad-Martin D.

Ear Hear. 2008 Dec;29(6):875-93. doi: 10.1097/AUD.0b013e318181ad99.

PMID:
18753950
3.

Ototoxicity risk assessment combining distortion product otoacoustic emissions with a cisplatin dose model.

Dille MF, McMillan GP, Reavis KM, Jacobs P, Fausti SA, Konrad-Martin D.

J Acoust Soc Am. 2010 Sep;128(3):1163-74. doi: 10.1121/1.3473693.

PMID:
20815453
4.

Evoked otoacoustic emissions--an approach for monitoring cisplatin induced ototoxicity in children.

Stavroulaki P, Apostolopoulos N, Segas J, Tsakanikos M, Adamopoulos G.

Int J Pediatr Otorhinolaryngol. 2001 May 31;59(1):47-57.

PMID:
11376818
5.

Characteristics and risk factors of cisplatin-induced ototoxicity in testicular cancer patients detected by distortion product otoacoustic emission.

Biro K, Noszek L, Prekopp P, Nagyiványi K, Géczi L, Gaudi I, Bodrogi I.

Oncology. 2006;70(3):177-84. Epub 2006 Jun 2.

PMID:
16757924
6.

[Detection of late ototoxic side effect of cisplatin by distortion otoacoustic emission (DPOAE)].

Biró K, Noszek L, Prekopp P, Nagyiványi K, Géczi L, Gaudi I, Bodrogi I.

Magy Onkol. 2006;50(4):329-35. Epub 2007 Jan 10. Hungarian.

7.

[Detection of ototoxic effect of cisplatin with otoacoustic emission in testicular cancer patients].

Biró K.

Magy Onkol. 2009 Sep;53(3):279-83. doi: 10.1556/MOnkol.53.2009.3.8. Hungarian.

8.

Progressive hearing loss after completion of cisplatin chemotherapy is common and more pronounced in children without spontaneous otoacoustic emissions before chemotherapy.

Weissenstein A, Deuster D, Knief A, Zehnhoff-Dinnesen AA, Schmidt CM.

Int J Pediatr Otorhinolaryngol. 2012 Jan;76(1):131-6. doi: 10.1016/j.ijporl.2011.10.020. Epub 2011 Nov 21.

PMID:
22104469
9.

Distortion product otoacoustic emissions: an objective technique for the screening of hearing loss in children treated with platin derivatives.

Dhooge I, Dhooge C, Geukens S, De Clerck B, De Vel E, Vinck BM.

Int J Audiol. 2006 Jun;45(6):337-43.

PMID:
16777780
10.

[Otoacoustic emissions measurements in children during the chemotherapy because of the acute lymphoblastic leukemia].

Lisowska G, Namysłowski G, Hajduk A, Polok A, Tomaszewska R, Misiołek M.

Otolaryngol Pol. 2006;60(3):415-20. Polish.

PMID:
16989457
11.

Ototoxicity from cisplatin therapy in childhood cancer.

Coradini PP, Cigana L, Selistre SG, Rosito LS, Brunetto AL.

J Pediatr Hematol Oncol. 2007 Jun;29(6):355-60.

PMID:
17551394
12.

Ototoxic effects of supradose cisplatin with sodium thiosulfate neutralization in patients with head and neck cancer.

Madasu R, Ruckenstein MJ, Leake F, Steere E, Robbins KT.

Arch Otolaryngol Head Neck Surg. 1997 Sep;123(9):978-81.

PMID:
9305250
13.

Distortion-product otoacoustic emission test performance for ototoxicity monitoring.

Reavis KM, McMillan G, Austin D, Gallun F, Fausti SA, Gordon JS, Helt WJ, Konrad-Martin D.

Ear Hear. 2011 Feb;32(1):61-74. doi: 10.1097/AUD.0b013e3181e8b6a7.

14.
15.

Left-right asymmetry in hearing loss following cisplatin therapy in children--the left ear is slightly but significantly more affected.

Schmidt CM, Knief A, Lagosch AK, Deuster D, am Zehnhoff-Dinnesen A.

Ear Hear. 2008 Dec;29(6):830-7. doi: 10.1097/AUD.0b013e31818005a4.

PMID:
18772725
16.

Ototoxicity screening of patients treated with streptomycin using distortion product otoacoustic emissions.

Md Daud MK, Mohamadl H, Haron A, Rahman NA.

B-ENT. 2014;10(1):53-8.

PMID:
24765829
17.

ABR obtained from time-efficient train stimuli for cisplatin ototoxicity monitoring.

Dille MF, Ellingson RM, McMillan GP, Konrad-Martin D.

J Am Acad Audiol. 2013 Oct;24(9):769-81. doi: 10.3766/jaaa.24.9.2.

18.

Accuracy of distortion-product otoacoustic emissions-based ototoxicity monitoring using various primary frequency step-sizes.

McMillan GP, Konrad-Martin D, Dille MF.

Int J Audiol. 2012 Sep;51(9):689-96. doi: 10.3109/14992027.2012.688143. Epub 2012 Jun 7.

19.

Effect of high-dose cisplatin on auditory brainstem responses and otoacoustic emissions in laboratory animals.

Sockalingam R, Freeman S, Cherny TL, Sohmer H.

Am J Otol. 2000 Jul;21(4):521-7.

PMID:
10912698
20.

Cisplatin ototoxicity in the Sprague Dawley rat evaluated by distortion product otoacoustic emissions.

Hatzopoulos S, Di Stefano M, Campbell KC, Falgione D, Ricci D, Rosignoli M, Finesso M, Albertin A, Previati M, Capitani S, Martini A.

Audiology. 2001 Sep-Oct;40(5):253-64.

PMID:
11688544

Supplemental Content

Support Center